VIGATO, CHIARA
 Distribuzione geografica
Continente #
NA - Nord America 273
EU - Europa 231
AS - Asia 39
AF - Africa 4
SA - Sud America 3
OC - Oceania 1
Totale 551
Nazione #
US - Stati Uniti d'America 270
IT - Italia 124
IE - Irlanda 48
GB - Regno Unito 20
IN - India 14
HK - Hong Kong 11
SE - Svezia 11
PT - Portogallo 8
DE - Germania 4
NG - Nigeria 4
SG - Singapore 4
ES - Italia 3
JP - Giappone 3
UA - Ucraina 3
CL - Cile 2
CZ - Repubblica Ceca 2
FR - Francia 2
IR - Iran 2
KR - Corea 2
MX - Messico 2
NL - Olanda 2
SK - Slovacchia (Repubblica Slovacca) 2
AU - Australia 1
BO - Bolivia 1
CA - Canada 1
CN - Cina 1
GR - Grecia 1
LV - Lettonia 1
TH - Thailandia 1
TW - Taiwan 1
Totale 551
Città #
Los Angeles 98
Dublin 48
Turin 43
Chandler 32
Rome 20
Milan 16
Nyköping 11
Ashburn 9
Lisbon 8
Lucknow 8
Bradford 6
Leeds 6
Abuja 4
Luni 4
Medford 4
Princeton 4
Alessandria 3
Barcelona 3
Florence 3
Garbagnate Milanese 3
Washington 3
Birmingham 2
Bratislava 2
Brooklyn 2
Gunzenhausen 2
Hradec Králové 2
Jacksonville 2
Manchester 2
Modena 2
Naples 2
New Hope 2
Osaka 2
Paddington 2
Rivoli 2
Scarborough 2
Talca 2
Wanchai 2
West Jordan 2
Amsterdam 1
Bangkok 1
Barletta 1
Basingstoke 1
Bengaluru 1
Berlin 1
Boston 1
Caltagirone 1
Candiac 1
Central 1
Cheonan 1
College Station 1
Gangdong-gu 1
Genzano di Roma 1
Grinzane Cavour 1
Guadalajara 1
Kanazawa 1
London 1
New York 1
Nice 1
Noicattaro 1
Polignano a Mare 1
Saluzzo 1
San Luis Potosí City 1
Santa Clara 1
Santa Cruz 1
Seattle 1
Singapore 1
Sydney 1
Trento 1
Vaprio D'adda 1
Verolanuova 1
Totale 402
Nome #
New inhibitors of Aldo-Keto Reductase 1C3 (AKR1C3) based on benzoisoxazole scaffold and their potential application in cancer 106
New Hydroxybenzoazole Inhibitors of Aldo-Keto Reductase 1C3 (AKR1C3): Disclosure of SAR Investigation to Target Prostate Cancer 77
Design of new human Dihydroorotate Dehydrogenase inhibitors: amide bioisosterism in MEDS433 optimization 68
Improvement of metabolic weakness of new human Dihydroorotate Dehydrogenase inhibitors based on 2-hydroxypyrazolo[1,5-a]pyridine scaffold 40
Targeting myeloid leukemias using human Dihydroorotate Dehydrogenase inhibitors based on 2-hydroxypyrazolo[1,5-a]pyridine scaffold: overcoming of metabolic issues 38
Application of an in house bioisosteric approach to the design of innovative inhibitors of aldo-keto reductase 1C3 (AKR1C3) 32
Targeting Myeloid Leukemias Using human Dihydroorotate Dehydrogenase Inhibitors Based on 2-Hydroxypyrazolo[1,5-a]pyridine Scaffold: Overcoming of Metabolic Issues 27
HYDROXYLATED HETEROCYCLES AS BIOISOSTERES OF THE CARBOXYLIC FUNCTION: DESIGN OF NEW AKR1C3 INHIBITORS ACTIVE IN PROSTATE CANCER 27
Targeting Acute Myelogenous Leukemia using potent human dihydroorotate dehydrogenase inhibitors based on the 2-hydroxypyrazolo[1,5-a]pyridine scaffold: from academy to clinic 26
Important steps into drug development of MEDS433, a potent human dihydroorotate dehydrogenase inhibitor based on the 2-hydroxypyrazolo[1,5-a]pyridine scaffold 25
Application of an in house bioisosteric approach to the design of innovative inhibitors of aldo-keto reductase 1C3 (AKR1C3) 22
Phenothiazines as anti-cancer agents: SAR overview and synthetic strategies 17
Important Steps into Drug Development of MEDS433, a Potent Human Dihydroorotate Dehydrogenase Inhibitor based on the 2-hydroxypyrazolo[1,5-a] Pyridine Scaffold 16
Improvement of Metabolic Weakness of New Dihydroorotate Dehydrogenase Inhibitors Based on 2-Hydroxypyrazolo[1,5-a]pyridine Scaffold to Target Myeloid Leukemias 16
Targeting Acute Myelogenous Leukemia using potent human dihydroorotate dehydrogenase inhibitors based on the 2- hydroxypyrazolo[1,5-a]pyridine scaffold: from academy to clinic 14
A new generation of AKR1C3 inhibitors on the horizon: the 3- hydroxybenzazole approach to target prostate cancer 12
Improvement of Metabolic Weakness of New Dihydroorotate Dehydrogenase Inhibitors Based on 2-Hydroxypyrazolo[1,5-a]pyridine Scaffold to Target Myeloid Leukemias 10
Optimization of MEDS433 synthesis: scale-up for preclinical evaluation studies 6
Structure-guided optimization of 3-hydroxybenzoisoxazole derivatives as inhibitors of Aldo-keto reductase 1C3 (AKR1C3) to target prostate cancer 4
Optimization of MEDS433 synthesis: scale-up for preclinical evaluation studies 4
Totale 587
Categoria #
all - tutte 2.967
article - articoli 0
book - libri 0
conference - conferenze 2.775
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 5.742


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/202244 0 0 0 0 0 0 0 0 0 10 21 13
2022/2023252 22 18 12 9 10 86 29 13 16 4 15 18
2023/2024291 30 25 14 14 12 26 133 13 4 20 0 0
Totale 587